Related references
Note: Only part of the references are listed.Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
Jing-Quan Wang et al.
DRUG RESISTANCE UPDATES (2021)
Insight into next-generation CAR therapeutics designing CAR T cells to improve clinical outcomes
Emiliano Roselli et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Muhlis Akman et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
Bin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Hypoxia and the phenomenon of immune exclusion
Violena Pietrobon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Phase 2 study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The oral HIF-2 [alpha] inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.
Todd Michael Bauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Yoshihiko Tomita et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
Othon Iliopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
Alexander Roberts et al.
SCIENTIFIC REPORTS (2021)
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Aparna Hegde et al.
CLINICAL CANCER RESEARCH (2021)
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K. Choueiri et al.
NATURE MEDICINE (2021)
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
Nataliia Petruk et al.
SCIENTIFIC REPORTS (2021)
Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
Guillermo O. Rangel Rivera et al.
FRONTIERS IN IMMUNOLOGY (2021)
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
Dan P. Zandberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Zhe Fu et al.
CELLS (2021)
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su et al.
DRUG RESISTANCE UPDATES (2021)
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
Sarah A. Ackroyd et al.
GYNECOLOGIC ONCOLOGY (2021)
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
Ramaprasad Srinivasan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.
Lu Si et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).
Elizabeth R. Plimack et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
Xing-chen Ding et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Chung-Han Lee et al.
LANCET ONCOLOGY (2021)
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Vicky Makker et al.
ONCOLOGIST (2021)
Metabolic barriers to cancer immunotherapy
Kristin DePeaux et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Choline phosphate lipid insertion and rigidification of cell membranes for targeted cancer chemo-immunotherapy
Shengran Li et al.
CHEMICAL COMMUNICATIONS (2021)
Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?
Joanna Kopecka et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Tumor angiogenesis: causes, consequences, challenges and opportunities
Roberta Lugano et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A. McGregor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Yuanyuan Jiang et al.
CANCER LETTERS (2020)
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Cristina P. Rodriguez et al.
CLINICAL CANCER RESEARCH (2020)
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab plus Bevacizumab versus Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma
Michael B. Atkins et al.
CLINICAL CANCER RESEARCH (2020)
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao et al.
DRUG RESISTANCE UPDATES (2020)
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Joanna Kopecka et al.
DRUG RESISTANCE UPDATES (2020)
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong et al.
DRUG RESISTANCE UPDATES (2020)
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Xichen Zheng et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combining microenvironment normalization strategies to improve cancer immunotherapy
Fotios Mpekris et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).
Dan Paul Zandberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
Andreas Nicholas Saltos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Alireza Labani-Motlagh et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane
Michal Stark et al.
CELLS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo et al.
DRUG RESISTANCE UPDATES (2020)
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Giovanna Li Petri et al.
BRITISH JOURNAL OF CANCER (2020)
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
Akio Tsutaho et al.
CELL COMMUNICATION AND SIGNALING (2020)
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodriguez-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2020)
Hypoxia Alters Epigenetic andN-Glycosylation Profiles of Ovarian and Breast Cancer Cell Linesin-vitro
Gordon Greville et al.
FRONTIERS IN ONCOLOGY (2020)
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma
Junhui Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
V. Morris et al.
ANNALS OF ONCOLOGY (2020)
Lactate Exposure Promotes Immunosuppressive Phenotypes in Innate Immune Cells
Rapeepat Sangsuwan et al.
CELLULAR AND MOLECULAR BIOENGINEERING (2020)
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Nir Shahar et al.
DRUG RESISTANCE UPDATES (2020)
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
Manuela Terranova-Barberio et al.
NATURE COMMUNICATIONS (2020)
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway
Xiaoxun Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer
Yuanyuan Wang et al.
JOURNAL OF IMMUNOLOGY (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways
Alexandra Giatromanolaki et al.
LIFE SCIENCES (2020)
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner et al.
MOLECULAR THERAPY (2020)
Targeting the HIF2-VEGF axis in renal cell carcinoma
Toni K. Choueiri et al.
NATURE MEDICINE (2020)
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin et al.
DRUG RESISTANCE UPDATES (2020)
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Perez-Ruiz et al.
DRUG RESISTANCE UPDATES (2020)
Cholesterol metabolism: At the cross road between cancer cells and immune environment
Joanna Kopecka et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2020)
Regulation of PD-L1 Expression by NF-κB in Cancer
Fabrizio Antonangeli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Dimas Carolina Belisario et al.
CELLS (2020)
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Xiaomin Cai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
CD163(+) tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes
Rodrigo Nalio Ramos et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Qing Cai et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Na+,HCO3- cotransporter NBCn1 accelerates breast carcinogenesis
Ebbe Boedtkjer
CANCER AND METASTASIS REVIEWS (2019)
Glioblastoma cancer stem cell biology: Potential theranostic targets
Farzaneh Sharifzad et al.
DRUG RESISTANCE UPDATES (2019)
Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors
Anna Schurich et al.
IMMUNOTHERAPY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization
Lisha Xiang et al.
CELL DEATH & DISEASE (2019)
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
Audrey Lequeux et al.
CANCER LETTERS (2019)
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Emily Hays et al.
DRUG RESISTANCE UPDATES (2019)
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
Axel Bex et al.
FUTURE ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Robert Berahovich et al.
CANCERS (2019)
Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
Edo Kon et al.
DRUG RESISTANCE UPDATES (2019)
The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela
Rosa Angela Cardone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
Rui Xu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Hannah Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The role of collagen in cancer: from bench to bedside
Shuaishuai Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis
Ines Godet et al.
NATURE COMMUNICATIONS (2019)
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
Jiali Cheng et al.
FRONTIERS IN ONCOLOGY (2019)
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
Karen G. de la Cruz-Lopez et al.
FRONTIERS IN ONCOLOGY (2019)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yi Yang et al.
CELL RESEARCH (2019)
CLIC4/Arf6 Pathway A New Lead in BMPRII Inhibition in Pulmonary Hypertension
Vahitha B. Abdul-Salam et al.
CIRCULATION RESEARCH (2019)
Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway
David Kung-Chun Chiu et al.
CELL DEATH & DISEASE (2019)
Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
Hong Luo et al.
FRONTIERS IN ONCOLOGY (2019)
The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells
L. Mai et al.
NEOPLASMA (2019)
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
Nilay Sethi et al.
JCI INSIGHT (2019)
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer
Xianmin Mu et al.
CELL CYCLE (2018)
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Thorsten Stiewe et al.
DRUG RESISTANCE UPDATES (2018)
Redundant angiogenic signaling and tumor drug resistance
Rajesh N. Gacche et al.
DRUG RESISTANCE UPDATES (2018)
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Xichen Zheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis
Mei-Zhen Zou et al.
SMALL (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
Xuejiao Song et al.
NANO LETTERS (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 alpha activation
Andrew G. Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Activation of LXR?/ by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
Soochi Kim et al.
BMC CANCER (2018)
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
Kaitlin Graham et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2018)
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity
Benny Zhitomirsky et al.
CELL DEATH & DISEASE (2018)
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
Stephen M. F. Jamieson et al.
JCI INSIGHT (2018)
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
Alexander Semaan et al.
VIRCHOWS ARCHIV (2017)
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Nicole E. Scharping et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
Carolina Cubillos-Zapata et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
New horizons in hypoxia signaling pathways
Christopher W. Pugh et al.
EXPERIMENTAL CELL RESEARCH (2017)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis
Ewelina Krzywinska et al.
NATURE COMMUNICATIONS (2017)
Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells
Michal Stark et al.
ONCOTARGET (2017)
Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
Chao Zhang et al.
ONCOTARGET (2017)
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
Benny Zhitomirsky et al.
ONCOTARGET (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression
Ayano Kondo et al.
CELL REPORTS (2017)
Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1
Federica Raggi et al.
FRONTIERS IN IMMUNOLOGY (2017)
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy
Raffaela Santoro et al.
DRUG RESISTANCE UPDATES (2017)
Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges
Yael Diesendruck et al.
DRUG RESISTANCE UPDATES (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3
Jaemoon Koh et al.
ONCOIMMUNOLOGY (2016)
Hypoxia-inducible factor 3 biology: complexities and emerging themes
Cunming Duan
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2016)
Biophysics in cancer: The relevance of drug-membrane interaction studies
Ana Catarina Alves et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2016)
Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells
Baoqing Guo et al.
BMC CANCER (2016)
Hypoxia regulates ABCG(2) activity through the activivation of ERK1/2/HIF-1 alpha and contributes to chemoresistance in pancreatic cancer cells
Xiaodan He et al.
CANCER BIOLOGY & THERAPY (2016)
The Multifaceted Role of Perivascular Macrophages in Tumors
Claire E. Lewis et al.
CANCER CELL (2016)
Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers
Takashi Kohnoh et al.
CANCER CELL INTERNATIONAL (2016)
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Curtis A. Clark et al.
CANCER RESEARCH (2016)
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
Kimberly J. Briggs et al.
CELL (2016)
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
Almut Brand et al.
Cell Metabolism (2016)
Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Wirginia Likus et al.
DRUG RESISTANCE UPDATES (2016)
Role of the tumor stroma in resistance to anti-angiogenic therapy
Elisabeth J. M. Huijbers et al.
DRUG RESISTANCE UPDATES (2016)
The bad seed: Cancer stem cells in tumor development and resistance
Elle Koren et al.
DRUG RESISTANCE UPDATES (2016)
Lysosomes as mediators of drug resistance in cancer
Benny Zhitomirsky et al.
DRUG RESISTANCE UPDATES (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer
Jian Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours
Katarzyna Stepien et al.
MEDICAL ONCOLOGY (2016)
Arf6 controls retromer traffic and intracellular cholesterol distribution via a phosphoinositide-based mechanism
Catherine Marquer et al.
NATURE COMMUNICATIONS (2016)
HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity
Hiroaki Semba et al.
NATURE COMMUNICATIONS (2016)
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
Joanna Kopecka et al.
ONCOTARGET (2016)
Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions
Gaspard Cretenet et al.
SCIENTIFIC REPORTS (2016)
Overcoming Hypoxia-Mediated Tumor Progression:Combinatorial Approaches Targeting pH Regulation,Angiogenesis and Immune Dysfunction
Paul C. McDonald et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1
Helena Doktorova et al.
BIOMEDICAL PAPERS-OLOMOUC (2015)
Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis
Justin V. Joseph et al.
CANCER LETTERS (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach
Sophie Taylor et al.
DRUG RESISTANCE UPDATES (2015)
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
Rishil J. Kathawala et al.
DRUG RESISTANCE UPDATES (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof
Tseng-Cheng Chen et al.
ORAL ONCOLOGY (2015)
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
Huimin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
Haiquan Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nikolaos Patsoukis et al.
NATURE COMMUNICATIONS (2015)
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
Joanna Kopecka et al.
ONCOTARGET (2015)
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
Micol Rigoni et al.
ONCOTARGET (2015)
Tumor hypoxia drives immune suppression and immunotherapy resistance
Midan Ai et al.
Journal for ImmunoTherapy of Cancer (2015)
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
Iris Chiara Salaroglio et al.
ONCOTARGET (2015)
Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
Benny Zhitomirsky et al.
ONCOTARGET (2015)
Palmitoylation of G alpha q Determines Its Association with the Thromboxane Receptor in Hypoxic Pulmonary Hypertension
Anuraq S. Sikarwar et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2014)
Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication
Dong Hoon Suh et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response
S. R. McKeown
BRITISH JOURNAL OF RADIOLOGY (2014)
The SIRT1/HIF2α Axis Drives Reductive Glutamine Metabolism under Chronic Acidosis and Alters Tumor Response to Therapy
Cyril Corbet et al.
CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
Darren M. Hutt et al.
PLOS ONE (2014)
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Erinn B. Rankin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
S. Raz et al.
CELL DEATH & DISEASE (2014)
Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
Michail V. Sitkovsky et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors
Olga Sedlakova et al.
FRONTIERS IN PHYSIOLOGY (2014)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
Mirna Balsamo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Gregg L. Semenza
JOURNAL OF CLINICAL INVESTIGATION (2013)
Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition
Giada Gelsomino et al.
MOLECULAR CANCER (2013)
Hypoxia Reduces the Efficiency of Elisidepsin by Inhibiting Hydroxylation and Altering the Structure of Lipid Rafts
Anna Kiraly et al.
MARINE DRUGS (2013)
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
Andrew L. Doedens et al.
NATURE IMMUNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The VHL/HIF axis in clear cell renal carcinoma
Chuan Shen et al.
SEMINARS IN CANCER BIOLOGY (2013)
Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia
Sensen Lin et al.
CANCER SCIENCE (2012)
Combining angiogenesis inhibition and radiotherapy: A double-edged sword
Esther A. Kleibeuker et al.
DRUG RESISTANCE UPDATES (2012)
HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5
Ainara Elorza et al.
MOLECULAR CELL (2012)
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy
Yi Li et al.
LEUKEMIA & LYMPHOMA (2012)
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Eric V. Dang et al.
CELL (2011)
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Asaka Kondo et al.
BLOOD (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation
Hongxia Z. Imtiyaz et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB
Nadine Rohwer et al.
PLOS ONE (2010)
Tumor Angiogenesis: Insights and Innovations
Fernando Nussenbaum et al.
JOURNAL OF ONCOLOGY (2010)
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
Holger K. Eltzschig et al.
BLOOD (2009)
Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance
Lili Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
Richard Sullivan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
C. A. Crane et al.
ONCOGENE (2009)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells
J. Hao et al.
CANCER GENE THERAPY (2008)
Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts
Renato Wirthner et al.
CARCINOGENESIS (2008)
Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway
William G. Kaelin et al.
MOLECULAR CELL (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes
I. Stuart Wood et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells
Eran E. Bram et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Karin Fischer et al.
BLOOD (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates
Eran Bram et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance
I Ifergan et al.
CANCER RESEARCH (2005)
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates
A Shafran et al.
CANCER RESEARCH (2005)
Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells
RNT Coffey et al.
CANCER (2005)
HIF-1, O2, and the 3 PHDs:: How animal cells signal hypoxia to the nucleus
GL Semenza
CELL (2001)
Share Paper
